Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 21;19(3):107–115. doi: 10.1200/OP.22.00226

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 1. — Treatment algorithm of immunotherapy-based regimens in esophagogastric cancer. Treatment algorithm for the use of immunotherapy in the metastatic setting for esophageal, gastroesophageal, and gastric cancer. IO is used with or without chemotherapy as mentioned and not all combinations are FDA-approved. ^aNCCN category 1 recommendation; ^bNCCN category 2A recommendation; ^cNCCN category 2B recommendation; ^dFDA-approved. CPS, combined positive score; FDA, US Food and Drug Administration; FUP, fluorouracil + platinum; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; IO, immunotherapy; Ipi, ipilimumab; Nivo, nivolumab; Pem, pembrolizumab; SCC, squamous cell carcinoma; T, trastuzumab.